header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-TALEN-190311-2
TALEN Name: TALEN1-scg2b
Target: scg2b (1)
Source:
Target Sequence 1:
5' - TCCCAGCTCCGATATGA - 3'
   
Select Sequence Analysis Tool

Target Sequence 2:
5' - TGCTTTAAGCTTTCGAT - 3'
   
Select Sequence Analysis Tool

  (Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.)
TARGET LOCATIONS
No data available
CONSTRUCTS WITH SEQUENCES FROM TALEN1-scg2b No data available
GENOMIC FEATURES CREATED WITH TALEN1-scg2b
Genomic Feature Affected Genomic Regions    
ihb603 scg2b    
ihb604 scg2b    
GENE EXPRESSION
Gene expression in Wild Types + TALEN1-scg2b No data available
PHENOTYPE
Phenotype resulting from TALEN1-scg2b
No data available

Phenotype of all Fish created by or utilizing TALEN1-scg2b
Phenotype Fish Conditions Figures
whole organism protein kinase B signaling decreased occurrence, abnormal scg2bihb603/ihb603(AB) standard conditions Fig. 5Fig. 6 from Tao et al., 2018
whole organism MAPK cascade occurrence, ameliorated scg2bihb603/ihb603(AB) chemical treatment by environment: N-arachidonoyl-L-serine Fig. 6 from Tao et al., 2018
hypophysis scg2a expression increased amount, abnormal scg2bihb603/ihb603(AB) standard conditions Fig. 2 from Tao et al., 2018
brain MAPK cascade decreased occurrence, abnormal scg2bihb603/ihb603(AB) standard conditions Fig. 5 from Tao et al., 2018
brain scg2b expression decreased amount, abnormal scg2bihb603/ihb603(AB) standard conditions Fig. 2 from Tao et al., 2018
whole organism protein kinase B signaling occurrence, ameliorated scg2bihb603/ihb603(AB) chemical treatment by environment: N-arachidonoyl-L-serine Fig. 6 from Tao et al., 2018
central artery MAPK cascade decreased occurrence, abnormal scg2bihb603/ihb603(AB) standard conditions Fig. 5 from Tao et al., 2018
whole organism MAPK cascade decreased occurrence, abnormal scg2bihb603/ihb603(AB) control Fig. 6 from Tao et al., 2018
central artery blood vessel morphogenesis occurrence, ameliorated scg2bihb603/ihb603 ; s843Tg(AB) chemical treatment by environment: N-arachidonoyl-L-serine Fig. 6 from Tao et al., 2018
central artery angiogenesis decreased occurrence, abnormal scg2bihb603/ihb603 ; s843Tg(AB) standard conditions Fig. 2 from Tao et al., 2018
central artery blood vessel morphogenesis decreased occurrence, abnormal scg2bihb603/ihb603 ; s843Tg(AB) control Fig. 6 from Tao et al., 2018
hindbrain central artery malformed, abnormal scg2bihb603/ihb603 ; s843Tg(AB) standard conditions Fig. 2Fig. 6 from Tao et al., 2018
central artery vasculature development decreased occurrence, abnormal scg2bihb603/ihb603 ; s843Tg(AB) standard conditions Fig. 2 from Tao et al., 2018
hindbrain central artery morphology, ameliorated scg2bihb603/ihb603 ; s843Tg(AB) chemical treatment by environment: N-arachidonoyl-L-serine Fig. 6 from Tao et al., 2018
central artery MAPK cascade decreased occurrence, abnormal scg2bihb603/ihb603 ; s843Tg(AB) standard conditions Fig. 5 from Tao et al., 2018
central artery blood vessel endothelial cell migration decreased rate, abnormal scg2bihb603/ihb603 ; s843Tg(AB) standard conditions Fig. 4 from Tao et al., 2018
central artery vascular endothelial cell proliferation decreased occurrence, abnormal scg2bihb603/ihb603 ; s843Tg(AB) standard conditions Fig. 4 from Tao et al., 2018
hypophysis scg2a expression absent, abnormal scg2aihb601/ihb601 ; scg2bihb603/ihb603(AB) standard conditions Fig. 2 from Tao et al., 2018
central artery angiogenesis decreased occurrence, abnormal scg2aihb601/ihb601 ; scg2bihb603/ihb603 ; s843Tg(AB) standard conditions Fig. 2 from Tao et al., 2018
hindbrain central artery malformed, abnormal scg2aihb601/ihb601 ; scg2bihb603/ihb603 ; s843Tg(AB) standard conditions Fig. 2 from Tao et al., 2018
central artery vasculature development decreased occurrence, abnormal scg2aihb601/ihb601 ; scg2bihb603/ihb603 ; s843Tg(AB) standard conditions Fig. 2 from Tao et al., 2018
OTHER TALEN1-scg2b TALEN PAGESNo links to external sites
CITATIONS (1)